Category Archives: LDK378 – Ceritinib from Novartis

Novartis announces positive results

Patients had progression free survival (PFS) of an average of 18 months when taking Novartis’ Zykadia (ceritinib) as their first ALK inhibitor for ALK+ Lung cancer. REMARKABLE! These patients had an objective response rate (ORR) of 72.3%. Zykadia achieved ORR … Continue reading

Posted in LDK378 - Ceritinib from Novartis | Leave a comment

Crizotinib / Ceritinib mutation study

Below is a link to a Cancer Discovery article, which found that biopsies of patients with crizotinib-resistant NSCLC, revealed that ceritinib potently overcomes crizotinib-resistant mutations. In particular, ceritinib effectively inhibits ALK harboring L1196M, G1269A, I1171T, and S1206Y mutations. However, they … Continue reading

Posted in Crizotinib - Xalkori from Pfizer, LDK378 - Ceritinib from Novartis, Research, Resistance to treatment | Leave a comment

Comparing new ALK inhibitors

Here is a video on cancergrace.org by Dr. Leena Gandhi of Dana-Farber talking about various new ALK inhibitors compared with Crizotinib. The video is sponsored by Genentech which is a sister company to Chugai, which created Alectinib, so some of … Continue reading

Posted in AP26113 from Ariad, Brain metastases, CH542802 - Alectinib from Chugai - Roche, Crizotinib - Xalkori from Pfizer, LDK378 - Ceritinib from Novartis, Lung cancer, Potential Treatments, Side Effects | Leave a comment

Abstracts from upcoming ASCO conference

Overall, I would say the results were disappointing, fewer patients had progressed far enough for meaningful results than I had hoped for. However, given that the data cut offs were usually around December and most of the trials were near … Continue reading

Posted in AP26113 from Ariad, Brain metastases, CH542802 - Alectinib from Chugai - Roche, LDK378 - Ceritinib from Novartis, RXDX-101 by Ignyta, TSR-011 from Tesaro, X-396 from Xcovrery | Leave a comment

List of 9 ALK Inhibitors

List of 9 ALK inhibitor drugs currently in clinical trials: FDA approved (but several trials ongoing) Novartis – Ceritinib Pfizer – Crizotinib FDA Breakthrough Status Chugai – Alectinib (filed NDA in Japan) Ongoing trials Ariad AP26113 Nerviano NMS-E628. (Licensed by … Continue reading

Posted in AP26113 from Ariad, CEP-37440, CH542802 - Alectinib from Chugai - Roche, Crizotinib - Xalkori from Pfizer, LDK378 - Ceritinib from Novartis, Lung cancer, NMS-E628, Potential Treatments, Regulatory applications & approvals, Research, RXDX-101 by Ignyta, TSR-011 from Tesaro, X-396 from Xcovrery | Leave a comment

FDA approves LDK378 (Ceritinib).

Novartis gains FDA approval for Zykadia(TM). Breakthrough therapy drug approved four months ahead of review completion goal date. http://www.novartis.com/newsroom/media-releases/en/2014/1776962.shtml http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm395299.htm For an interesting commentary see: http://cancergrace.org/lung/2014/04/30/new-approval-for-zykadia-ldk378ceritinib-in-alk-positive-nsclc-why-it-matters-even-if-youre-not-alk-positive/#more-14473

Posted in Brain metastases, LDK378 - Ceritinib from Novartis, Lung cancer, Potential Treatments, Regulatory applications & approvals, Resistance to treatment, Side Effects | Leave a comment

ESMO – Next Generation ALK Inhibitors

Here is a summary of a presentation on next generation ALK inhibitors. ESMO Presentation

Posted in AP26113 from Ariad, CH542802 - Alectinib from Chugai - Roche, LDK378 - Ceritinib from Novartis, Lung cancer, Potential Treatments, Regulatory applications & approvals, Research, Resistance to treatment, Side Effects | Leave a comment

Grace has posted videos from the Santa Monica ALK patient forum

CancerGrace.org has posted nine videos from a February 24, 2014 patient forum. There were four doctors doing research on ALK+ Lung Cancer who discussed topics and answered questions. They included Dr. Alice Shaw, Dr. Ross Camidge, Dr. Jared Weiss, and … Continue reading

Posted in AP26113 from Ariad, Brain metastases, CH542802 - Alectinib from Chugai - Roche, Crizotinib - Xalkori from Pfizer, Experiences, LDK378 - Ceritinib from Novartis, Lung cancer, Potential Treatments, Research, Resistance to treatment, Side Effects | Leave a comment

LDK378 (Ceritinib) Study Published in NEJM

A couple of people have kindly pointed out that I have been reading these medical studies for too long and I am starting to sound like them. For short summary see bottom of post. So here is an attempt to … Continue reading

Posted in Brain metastases, LDK378 - Ceritinib from Novartis, Lung cancer, Potential Treatments, Regulatory applications & approvals, Research, Resistance to treatment, Side Effects | Leave a comment

Video on 2nd generation ALK Inhibitors

Here is a 7 minute video of several doctors discussing second generation ALK inhibitors. http://www.onclive.com/peer-exchange/nsclc-outcomes/Second-Generation-ALK-Inhibitors-in-NSCLC

Posted in AP26113 from Ariad, Brain metastases, LDK378 - Ceritinib from Novartis, Lung cancer, Potential Treatments, Research, Resistance to treatment, Side Effects | Leave a comment